OBJECTIVE: The authors previous studies documented persistence of multidrug resistance (MDR) acquired in five primary HIV-1 infection (PHI) cases for 1-2 years in the absence of antiretroviral treatment. This study characterizes the evolution of transmitted wild-type (WT) (n = 15), resistant (n = 10), and MDR (n = 6) infections. Long-term persistence of MDR infections (2-7 years), leading to one observed MDR superinfection is documented. METHODS: Genotypic changes in circulating viral quasi-species were evaluated over 1.5-7 years in patients (n = 31) enrolled in the PHI study. Sequencing of reverse transcriptase and protease regions identified nucleotide substitutions in the viral quasi-species and mutations at sites implicated in resistance to antiretroviral drugs. Phylogenetic and clonal analysis were performed to confirm one observed superinfection. RESULTS: Patients acquiring WT, drug-resistant and MDR infections showed little quasi-species evolution (> 99.6% homology) for more than 1.5 years, regardless of route of transmission. Transmitted resistance mutations (other than 184V) persisted for 2-7 years. MDR persistence in two PHI cases contrasted with the corresponding rapid reversion of MDR infections to WT in their partners following treatment interruption. One MDR transmission eliciting low-level viremia resulted in clearance of the original MDR infection followed by re-infection with a second heterologous MDR strain from a different partner. Phylogenetic and clonal analysis of source and index partner confirmed the superinfection. Both MDR species showed approximately 13-fold reductions in replication capacity relative to the homologous WT strain isolated from the source partner. CONCLUSIONS: Genotypic analysis in PHI may identify superinfection and MDR infections that represent important determinants of virological and treatment outcome.
OBJECTIVE: The authors previous studies documented persistence of multidrug resistance (MDR) acquired in five primary HIV-1 infection (PHI) cases for 1-2 years in the absence of antiretroviral treatment. This study characterizes the evolution of transmitted wild-type (WT) (n = 15), resistant (n = 10), and MDR (n = 6) infections. Long-term persistence of MDR infections (2-7 years), leading to one observed MDR superinfection is documented. METHODS: Genotypic changes in circulating viral quasi-species were evaluated over 1.5-7 years in patients (n = 31) enrolled in the PHI study. Sequencing of reverse transcriptase and protease regions identified nucleotide substitutions in the viral quasi-species and mutations at sites implicated in resistance to antiretroviral drugs. Phylogenetic and clonal analysis were performed to confirm one observed superinfection. RESULTS:Patients acquiring WT, drug-resistant and MDR infections showed little quasi-species evolution (> 99.6% homology) for more than 1.5 years, regardless of route of transmission. Transmitted resistance mutations (other than 184V) persisted for 2-7 years. MDR persistence in two PHI cases contrasted with the corresponding rapid reversion of MDR infections to WT in their partners following treatment interruption. One MDR transmission eliciting low-level viremia resulted in clearance of the original MDR infection followed by re-infection with a second heterologous MDR strain from a different partner. Phylogenetic and clonal analysis of source and index partner confirmed the superinfection. Both MDR species showed approximately 13-fold reductions in replication capacity relative to the homologous WT strain isolated from the source partner. CONCLUSIONS: Genotypic analysis in PHI may identify superinfection and MDR infections that represent important determinants of virological and treatment outcome.
Authors: Matt A Price; Carole L Wallis; Shabir Lakhi; Etienne Karita; Anatoli Kamali; Omu Anzala; Eduard J Sanders; Linda-Gail Bekker; Rogers Twesigye; Eric Hunter; Pontiano Kaleebu; Kayitesi Kayitenkore; Susan Allen; Eugene Ruzagira; Mary Mwangome; Gaudensia Mutua; Pauli N Amornkul; Gwynn Stevens; Sergei L K Pond; Malinda Schaefer; Mary A Papathanasopoulos; Wendy Stevens; Jill Gilmour Journal: AIDS Res Hum Retroviruses Date: 2010-11-23 Impact factor: 2.205
Authors: Amin S Hassan; Shalton M Mwaringa; Clare A Obonyo; Helen M Nabwera; Eduard J Sanders; Tobias F Rinke de Wit; Patricia A Cane; James A Berkley Journal: AIDS Res Hum Retroviruses Date: 2012-09-11 Impact factor: 2.205
Authors: Guinevere Q Lee; David R Bangsberg; Conrad Muzoora; Yap Boum; Jessica H Oyugi; Nneka Emenyonu; John Bennett; Peter W Hunt; David Knapp; Chanson J Brumme; P Richard Harrigan; Jeffrey N Martin Journal: AIDS Res Hum Retroviruses Date: 2014-07-29 Impact factor: 2.205
Authors: Mary S Campbell; Geoffrey S Gottlieb; Stephen E Hawes; David C Nickle; Kim G Wong; Wenjie Deng; Thomas M Lampinen; Nancy B Kiviat; James I Mullins Journal: PLoS One Date: 2009-05-28 Impact factor: 3.240